Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

Cantor Fitzgerald analyst Charles Duncan initiated coverage with a Buy rating on Marinus (MRNS – Research Report) yesterday and set a ...

AbbVie obtained emraclidine, a potential novel M4-selective positive allosteric modulator (PAM), originally commercialised by ...

Scientists have pinpointed the binding site for low-dose ketamine on NMDA receptors, explaining its fast-acting effects on ...

Beijing Primegene Therapeutics Co. Ltd. has patented macrocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) allosteric inhibitors reported to be useful for the ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

The key difference between emraclidine and Cobenfy is that emraclidine is a selective allosteric M4 agonist which means it ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...